Prestige Biologics said on the 23rd it signed a contract manufacturing organization (CMO) deal worth 6 billion won with an overseas biotech company.
The deal is a work order (WO) under a master service agreement (MSA) for long-term cooperation on biopharmaceutical production. The counterparty is a biopharmaceutical research and development company, and the specific company name was not disclosed due to the need to keep business information confidential.
The contract covers contract manufacturing of biopharmaceuticals and stability testing. The contract period runs from the contract date through June 30, 2032.
The contract amount is $4,103,800 (60.65 billion won), equivalent to 48.39% of Prestige Biologics' recent sales.
Work is scheduled from May 2026 to Feb. 2027. A separate stability test is planned from Nov. 2026 to Feb. 2032.
A company official said, "Based on our state-of-the-art GMP (good manufacturing practice) facilities with a total capacity of 154,000 liters (L) in Osong, North Chungcheong, we will stably supply high-quality biopharmaceuticals and continue to expand opportunities for additional orders."